Platinum-based doublet chemotherapy with or without bevacizumab is the standard treatment for untreated advanced nonsquamous non-small-cell lung cancer (NS-NSCLC). However, adding bevacizumab to chemotherapies other than paclitaxelcarboplatin is, though widely applied clinically, largely unjustified due to the lack of head-to-head data. We performed a Bayesian network meta-analysis (NMA) to address this important issue. Data of 8,548 patients from 18 randomized controlled trials (RCTs) receiving six treatments, including taxane-platinum (Taxane-Pt), gemcitabine-platinum (Gem-Pt), pemetrexed-platinum (Pem-Pt), taxane-platinum 1 bevacizumab (Taxane-Pt 1 B), gemcitabine-platinum 1 bevacizumab (GemPt 1 B) and pemetrexed-platinum 1 bevacizumab (Pem-Pt 1 B), were incorporated into the analyses. Direct and indirect evidence of overall survival (OS) and progression-free survival (PFS) were synthesized at the hazard ratio (HR) scale and evidence of objective response rate (ORR) and serious adverse events (SAE) were synthesized at the odds ratio (OR) scale. Taxane-Pt 1 B showed significant advantages in OS (HR 5 0.79, p < 0.001), PFS (HR 5 0.54, p < 0.001) and ORR (OR 5 2.7, p < 0.001) over Taxane-Pt with comparable tolerability (OR 5 3.1, p 5 0.08). Gem-Pt 1 B showed no OS benefit compared to any other treatment. No significant differences were detected between Pem-Pt 1 B and Pem-Pt in four outcomes. In terms of the benefit-risk ratio, Pem-Pt and Taxane-Pt 1 B were ranked the first and second, respectively. In conclusion, in the first-line treatment for advanced NS-NSCLC, Taxane-Pt and Gem-Pt are the most and least preferable regimens to be used with bevacizumab, respectively. Adding bevacizumab to Pem-Pt remains unjustified because it fails to improve efficacy or tolerability. In terms of the benefit-risk ratio, Pem-Pt and Taxane-Pt 1 B are the best and second-best treatment for this population.
Introduction
Platinum-based doublet chemotherapy is the current standard treatment for untreated advanced nonsquamous non-smallcell lung cancer (NS-NSCLC) patients with a performance status of 0-1. [1] [2] [3] Clinical regimens commonly used with platinum include paclitaxel, docetaxel, gemcitabine and pemetrexed. The landmark trial by Scagliotti et al. 4 established the superiority of pemetrexed to gemcitabine for advanced NS-NSCLC in the first-line setting. Thereafter, pemetrexedplatinum (Pem-Pt) becomes the preferred frontline treatment for untreated advanced NS-NSCLC patients. 2, 3 Bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), showed clinical benefits for untreated advanced NS-NSCLC in combination with paclitaxel-carboplatin (Taxane-Pt) in several randomized controlled trials (RCTs). [5] [6] [7] [8] Ever since, bevacizumab has been used with different platinum-based doublets in the first-line treatment for advanced NS-NSCLC, in an attempt to enhance the efficacy of chemotherapy. However, despite the demonstrated benefits of bevacizumab plus Taxane-Pt (Taxane-Pt 1 B), adding bevacizumab to other chemotherapy regimens for untreated advanced NS-NSCLC remains controversial. Bevacizumab plus gemcitabine-cisplatin (Gem-Pt 1 B), which was only assessed in a phase III RCT by Reck et al. (the AVAiL study (NCT00806923)), showed improved progression-free survival (PFS) and an objective response rate (ORR) with increased toxicity and similar overall survival (OS) comparing to GemPt alone. 9, 10 The lack of direct comparison between bevacizumab plus pemetrexed-platinum (Pem-Pt 1 B) and Pem-Pt alone remains a major gap in the current evidence and casts serious doubts on the use of Pem-Pt 1 B for this population. The European Society for Medical Oncology (ESMO) guidelines 1 and the National Comprehensive Cancer Network (NCCN) guidelines 3 both recommend Gem-Pt 1 B and
Pem-Pt 1 B in the first-line treatment for advanced NS-NSCLC, while the American Society of Clinical Oncology (ASCO) guidelines 2 exclude them for this population. Furthermore, although two head-to-head randomized controlled trials (RCTs) assessing Taxane-Pt 1 B and Pem-Pt both reported highly comparable efficacy and tolerability between them, 11, 12 the interchangeability of the triplet and doublet chemotherapy remains questionable.
Given the multiple treatments for untreated advanced NS-NSCLC and the absence of direct evidence comparing pairwise treatments, a network meta-analysis (NMA), enabling indirect comparisons to account for missing head-to-head data and multiple treatment comparisons, [13] [14] [15] [16] is needed to answer the aforementioned questions.
To address this need, we performed a Bayesian network meta-analysis to estimate the relative efficacy and tolerability of bevacizumab in combination with different platinumbased doublets in the first-line treatment for advanced NS-NSCLC, attempting to identify the most and least preferable regimen to be used with bevacizumab for this population. We also sought to fill the gap in the current literature by providing more information on the relative benefit and risk of Pem-Pt 1 B. Finally, we aimed to evaluate the comparative efficacy and tolerability of Taxane-Pt 1 B and Pem-Pt to further inform the selection of treatments for untreated advanced NS-NSCLC patients.
Material and Methods

Search strategy and selection criteria
Our systemic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and MetaAnalyses (PRISMA) guidelines. 17 Methods implemented were based on the Technical Support Documents (TSDs) of the National Institute for Health and Care Excellence Decision Support Unit (NICE DSU). [18] [19] [20] First, we systematically searched PubMed, EMBASE, Cochrane Central Register of Controlled Trials databases and ClinicalTrials.gov until the end of June 2017 using a combination of terms including, "NSCLC," "(advanced) or (metastatic) or (stage IV) or (stage IIIB)," "(first-line) or (untreated) or (chemo na€ ıve) or (front line)" and "(avastin) or (bevacizumab)." We then manually screened conferences abstracts, bibliographies of related reviews and included trials for potentially eligible articles.
The search was performed independently by two investigators (Z-S, G-FF).
To facilitate evidence synthesis, commonly used platinumbased doublets with and without bevacizumab for untreated advanced NS-NSCLC were classified into six categories, taxane-platinum chemotherapy (Taxane-Pt), gemcitabine-platinum chemotherapy (Gem-Pt), pemetrexed-platinum chemotherapy (Pem-Pt), taxane-platinum plus bevacizumab What's new? Patients with untreated advanced nonsquamous non-small-cell lung cancer (NS-NSCLC) typically are treated with a combination of platinum (Pt) and a second chemotherapeutic drug. Bevacizumab may be added to the doublet regimen, though whether its use is beneficial remains unclear. Here, in a meta-analysis of published trials involving NSCLC patients, bevacizumab combined with Pt-carboplatin (Taxane-Pt) was found to confer a significant survival advantage, while gemcitabine-Pt (Gem-Pt) plus bevacizumab showed no benefit over other treatments. Pemetrexed-Pt (Pem-Pt) plus bevacizumab and Pem-Pt had similar efficacy and tolerability. Pem-Pt and Taxane-Pt plus bevacizumab exhibited the best benefit-risk ratios for the study population.
(Taxane-Pt 1 B), gemcitabine-platinum plus bevacizumab (Gem-Pt 1 B) and pemetrexed-platinum plus bevacizumab (Pem-Pt 1 B).
Phases II/III randomized controlled trials (RCTs) and prospective studies that assessed at least two of the above treatments in the first-line setting for advanced NS-NSCLC were deemed eligible and included. Studies were excluded if they: (1) were single-arm or dosage-finding studies; (2) used bevacizumab in combination with treatments other than platinum-based doublets, such as tyrosine kinase inhibitors (TKIs) or immunotherapies or (3) assessed the role of bevacizumab in maintenance or subsequent treatments. Studies that involved a small proportion of squamous histology were also included in the analysis for the robustness of final results. 18 A sensitivity analysis excluding trials involving squamous histology was performed to justify their inclusion.
Data extraction and quality assessment
Two investigators (Z-S, G-FF) independently reviewed eligible studies in detail and extracted data pertaining to (1) bibliographic information; (2) patient characteristics; (3) study outcomes and (4) information related to quality assessments in an electronic database, which was later proofread by a third investigator (Z-YX). In the case of multi-arm trials comparing two different dosages of one agent to another, we retained the dosage adopted more widely in clinical practice. For multi-arm trials using the same category of agents for different arms, we combined results of those arms based on the predefined six treatments. Risk of bias of each study was assessed by another two investigators (Z-YX, Z-ZH) independently using the Cochrane risk of bias tools. 21 Discrepancies were discussed by all investigators until consensus was reached.
Outcome measures
The primary outcome was overall survival (OS). The secondary outcomes included progression-free survival (PFS) and the objective response rate (ORR) for efficacy and treatmentrelated serious (grades 3-4) adverse events (SAE) for tolerability. For survival outcomes (OS, PFS), hazard ratios (HRs) were used for analysis as they could account for censoring and reserve time-to-event information. 22 When HRs were not directly retrievable, we estimated them from the reported median survival time, corresponding confidence intervals (CIs) and p-values using the method described by Tierney et al. 22, 23 For multi-arm trials where the standard errors of the log hazards of common comparators were not available, we calculated them based on the method described by Woods et al. 24 As for dichotomous outcomes (ORR and SAE), incident numbers and sample sizes were directly extracted and pooled for meta-analysis. For the analysis of SAE, data on the overall numbers of patients with SAE were directly extracted and pooled if they were reported in the published article. If only the numbers of individual SAE were reported separately in articles, we used the largest number of grades 3-4 leukopenia, thrombocytopenia and anemia to represent the overall number of hematological SAE. 20 The relative effects of each comparison were reported as pooled estimates of HR for OS and PFS, and OR for ORR and SAE with corresponding 95% confidence intervals (CIs). HR <1 for OS and PFS, or OR >1 for ORR suggested preferable efficacy in the intervention group, while OR >1 for SAE suggested better tolerability in the control group.
Statistical analysis
For pairwise comparisons where direct evidence existed, heterogeneity was assessed with the I 2 statistic and p-values. Evidence was pooled in pairwise meta-analyses (PWMA) using random-effect models if p-values <0.1; otherwise we employed fixed-effect models to provide pooled estimates of direct comparisons. PWMA was performed with STATA (version 13.0). Funnel plots, Begg's and Egger's tests were used to detect publication bias. 25 The Bayesian network-meta analysis (NMA) was performed with JAGS and the GeMTC package in R (https:// drugis.org/software/r-packages/gemtc) in a random-effect model using Markov chain Monte Carlo methods. 26, 27 We assigned a non-informative uniform prior distribution to the parameters. For each outcome, three Markov chains with different starting values, generated using the method described by Gelman and Rubin, 26 were run in parallel for 100,000 iterations (300,000 in total) to obtain the posterior distribution. We used 20,000 burn-ins and a thinning interval of 50 for each chain. Convergence of iterations was assessed with the Brooks-Gelman-Rubin statistic. 28 All tests were two-sided. Results were deemed statistically significant with p-values <0.05 or 95% CIs excluding one.
The PWMA and NMA results were compared to roughly assess the consistency between the direct and indirect evidence, which was then statistically confirmed by nodesplitting analyses. 29 Node-splitting analysis was used because it's more sophisticated and robust in the case of a complex network with multi-arm trials. 30, 31 Treatment rankings in terms of each outcome were indicated by ranking probabilities. The surface under the cumulative ranking curves (SUCRA) was used to provide a simple numerical summary of treatment rankings. 32 For each outcome, SUCRA equals one if the treatment is certain to be ranked the first and zero if it's certain to be the last. 32 To jointly compare the efficacy and tolerability of each treatment and to assess their benefit-risk ratios, we ranked them based simultaneously on the SUCRA value of OS and tolerability (1-SUCRA SAE ) in the ranking plot.
Results
Eligible studies and patient characteristics
After initial search, 1,675 relevant records were identified and 57 potentially eligible full text articles were retrieved for detailed review. Eventually, we included 19 articles (18 RCTs), with a total of 8,548 patients randomized to receive the six aforementioned treatments, in this NMA (Fig. 1) . Nine of the included trials had bevacizumab-containing treatments in at least one arm (bevacizumab-containing subset). Among them, eight compared bevacizumab plus platinum-based chemotherapy with chemotherapy alone [5] [6] [7] [8] [9] [10] [11] [12] 33 and one compared two different bevacizumab-containing treatments. 34 The remaining nine compared the three platinum-based doublets chemotherapies with each other (bevacizumab-null subset). 4, [35] [36] [37] [38] [39] [40] [41] [42] Overall, 2,294 patients were randomly assigned to bevacizumab-containing treatments and 6,254 to platinumbased chemotherapies alone. Standard dosages and administration schemes of platinum-based chemotherapies and bevacizumab were used in all trials, except for Boutsikou et al.,
33 which used 7.5 mg/kg bevacizumab. The demographic and clinical characteristics of involved patients were generally well-balanced between different trials and different arms within each trial. All included trials involved stage IV NSCLC patients with a performance status of 0-1 predominantly. All trials [5] [6] [7] [8] [9] [10] [11] [12] 33, 34 in the bevacizumab-containing subset and two trials in the bevacizumab-null subset 41, 42 involved nonsquamous histology exclusively. Seven trials in the bevacizumab-null subset 4, [35] [36] [37] [38] [39] [40] involved a small proportion of squamous histology and three of them 4, 36, 39 provided data for nonsquamous subgroups. For the analysis of primary outcomes, HRs were explicitly reported in 13 trials. Five trials 7, 36, 37, 39, 40 reported median survival durations with p-values. For Schiller, 36 a four-arm trial assessing paclitaxel-cisplatin, docetaxel-cisplatin, paclitaxel-carboplatin and gemcitabine-cisplatin, we combined results of the former three arms into Taxane-Pt for the convenience of analysis. Detailed characteristics of all the included trials are listed in Table 1 .
As for the risks of bias, one trial (Boutsikou et al. 33 ) was rated with high overall risk of bias, as it had three rated with an unclear risk of bias. Among the remaining trials, eleven trials had two items and three trials had one item rated with unclear risk of bias. Detailed results of the risks of bias assessment are included in the Supplementary Materials 1.
Network for network meta-analysis Figure 2 shows the network established for network metaanalyses for four outcomes. There were 15 pairwise comparisons in total. Among them, seven were mixed comparisons, which combined direct and indirect evidence, and eight were indirect comparisons. Two of the three bevacizumab-containing treatments had direct comparisons to at least one kind of bevacizumab-null platinum-based doublets, except for Pem-Pt 1 B, which was only compared to Taxane-Pt 1 B in one trial. 34 Taxane-Pt 1 B was compared to Taxane-Pt in five trials [5] [6] [7] [8] 33 and to Pem-Pt in two trials. 11, 12 Since no significant heterogeneity was detected, direct evidence regarding these two pairwise comparisons were pooled in pairwise meta-analyses (PWMA) using fixed-effect models. Details of the PWMA and the corresponding NMA results were presented in Figure 3 . In accordance with previous RCTs and meta-analyses, [5] [6] [7] 11, 12, [43] [44] [45] our PWMA results showed that, Taxane-Pt 1 B led to significant improvements in OS (HR 5 0.78, 95% CI: 0.69-0.90, p < 0.001), PFS (HR 5 0.50, 95% CI: 0.37-0.69, p < 0.001) and ORR (OR 5 3.0, 95% CI: 2.4-3.8, p < 0.001) with reduced tolerability (SAE: OR 5 3.0, 95% CI: 2.7-23, p < 0.001) in comparison to Taxane-Pt. Compared to Pem-Pt, Taxane-Pt 1 B were marginally superior in efficacy and inferior in tolerability without significant difference. According to Begg's and Egger's tests (p > 0.05), no publication bias was detected and all shapes of the funnels were close to symmetric.
Notably, two treatments (vinorelbine-Pt and irinotecanPt) were introduced by two multi-arm trials 35, 38 respectively for a more connected network. They were not included in the decision comparator set because they are not commonly used clinically. We included them in the synthesis comparator set to make the final results less sensitive to the inclusion and exclusion of any individual trial.
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Network meta-analysis for efficacy and tolerability
Results of the NMA were presented in Table 2 . All trials listed were included in the analysis of the primary outcome. In terms of OS, Taxane-Pt 1 B showed significant advantage over Taxane For the secondary outcomes, all trials except Gronberg et al., 39 which was not designed to assess PFS and ORR, were included in the analysis. In terms of both PFS and ORR, Taxane-Pt 1 B was significantly more preferable to the three bevacizumab-null chemotherapies (PFS: Taxane-Pt: HR 5 0.54, 95% CI: 0.44-0.68, p < 0.001; Gem-Pt: HR 5 0.59, Figure 2 . Network of all eligible trials assessing the six treatments in the first-line setting for advanced NS-NSCLC established for the Bayesian network meta-analysis. The size of the nodes is proportional to the number of patients (in parentheses) randomized to receive the treatment. The width of the lines is proportional to the number of trials (beside the line) comparing the connected treatments (nodes). TaxanePt 1 B, taxane-platinum plus bevacizumab; Gem-Pt 1 B, gemcitabine-platinum plus bevacizumab; Pem-Pt 1 B, pemetrexed-platinum plus bevacizumab; Taxane-Pt, taxane-platinum chemotherapy; Gem-Pt, gemcitabine-platinum chemotherapy; Pem-Pt, pemetrexed-platinum chemotherapy; Vin-Pt, vinorelbine-platinum chemotherapy; Iri-Pt, irinotecan-platinum chemotherapy. In terms of tolerability, the overall numbers of SAE were directly retrievable in nine studies, 5, 6, [10] [11] [12] 16, 33, 34, 36, 37 and were calculated using the methods aforementioned in the other nine studies. 4, 7, 8, 35, [37] [38] [39] [40] [41] For the evaluation of SAE, eight studies 4, 5, 7, [35] [36] [37] [38] 40 used the National Cancer Institute Common Toxicity Criteria version 2.0, eight studies [8] [9] [10] [11] 33, 34, 39, 41, 42 used the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 and two studies 6, 11 used CTCAE version 4.0. Results of our NMA showed that all bevacizumab-containing treatments tended to have reduced tolerability compared to platinum-based chemotherapies alone. But only Taxane-Pt 1 B (OR 5 7.6, 95% CI: 1.5-43, p 5 0.01) showed significantly higher risk of SAE in comparison to Pem-Pt. No significant differences were detected among the three bevacizumab-containing treatments in all outcomes. In terms of efficacy, Gem-Pt 1 B tended to be the least preferable combination. Taxane-Pt 1 B and Pem-Pt 1 B had highly comparable OS (HR 5 1.0, 95% CI: 0.83-1.2, p 5 1.00). However, in terms of tolerability, Taxane-Pt 1 B tended to be the most tolerated while Pem-Pt 1 B tended to be the last.
Inconsistency assessment and treatment ranking
The NMA results were highly comparable to the PWMA results in terms of efficacy and tolerability (Fig. 3) , which suggested the consistency between the direct and indirect evidence. There were two independent closed loops in the network: Taxane-Pt-Taxane-Pt 1 B-Pem-Pt and TaxanePt-Gem-Pt-Pem-Pt. We evaluated the network inconsistency based on the two loops using node-splitting analyses for four outcomes (Supplementary Materials 3A) . In addition, given the marginal p-values in the node-splitting analysis for ORR and the wide 95% CI of the NMA results for SAE, we further assessed the inconsistency of these two outcomes by calculating their inconsistency standard deviations (ISD) and To further assess the benefit-risk ratios of the six treatments simultaneously, we ranked them based on the SUCRA values of OS and tolerability (1-SUCRA SAE ) in the ranking plot (Fig. 4) . According to the ranking plot, Pem-Pt appeared to be the optimal first-line treatment for advanced NS-NSCLC for it had the best benefit-risk ratio (Fig. 4 : the right upper quadrant of the ranking plot). Taxane-Pt 1 B and Pem-Pt 1 B were ranked the second and third respectively for their good efficacy but poor tolerability (Fig. 4 : right lower quadrant of the ranking plot). Sensitivity analyses omitting the trial with high overall risk of bias 33 and trials involving squamous histology 35, 37, 38, 40 did not affect the main results (Supplementary Materials 4) . These trials were therefore all included for the robustness of final results.
Discussion
To our knowledge, this is the first and the most comprehensive network meta-analysis assessing the comparative efficacy and tolerability of bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced NS-NSCLC. By far, the added value of bevacizumab to chemotherapy regimens other than paclitaxel-carboplatin remains unknown. Adding bevacizumab to Gem-Pt or Pem-Pt for this population is, though widely applied clinically, largely unjustified due to the lack of head-to-head data between them.
In our study, we used Bayesian NMA to estimate the comparative efficacy and tolerability of bevacizumab in combination with different platinum-based doublets for untreated advanced NS-NSCLC patients, aiming to identify the most and least preferable chemotherapy regimens to be used with bevacizumab in the clinical setting. We also filled the gap in current evidence by elucidating the relative benefit and risk of adding bevacizumab to Pem-Pt. Furthermore, we attempted to provide readers with more information to make evidence-based decisions about the selection of Taxane-Pt 1 B and Pem-Pt in the first-line treatment for advanced NS-NSCLC. Based on our NMA results, three main conclusions of clinical significance can be drawn.
First, our results suggest that in the first-line treatment for advanced NS-NSCLC, Taxane-Pt and Gem-Pt are the most and least preferable regimens to be used with bevacizumab, respectively. Adding bevacizumab to platinum-based doublets in the first-line treatment for advanced NS-NSCLC has always been controversial. Regarding this issue, the European guidelines (European Society for Medical Oncology (ESMO) 1 ) and two American guidelines (American Society of Clinical Oncology (ASCO), 2 National Comprehensive Cancer Network (NCCN) 3 ) give different recommendations. The ESMO guidelines and the NCCN guidelines both recommend that when platinum-based chemotherapy is indicated, a combination with bevacizumab should be considered for eligible patients with NS-NSCLC and a PS 5 0-1. 1, 3 However, the ASCO guidelines 2 suggest that paclitaxel-carboplatin is the only regimen for which current evidence supports the addition of bevacizumab, while no sufficient evidence supports the addition of bevacizumab to other platinum-based doublets. Consistent with the ASCO guidelines, our findings further confirm that the additional benefits of adding bevacizumab to platinum-based chemotherapy depends on the chemotherapy regimen itself. In the first-line treatment for advanced NS-NSCLC, Taxane-Pt is the best regimen to be used with bevacizumab. According to our results, TaxanePt 1 B led to significant efficacy improvements with comparable tolerability in comparison to Taxane-Pt, while GemPt 1 B showed modest PFS and ORR advantages with highly similar OS in comparison to Gem-Pt. No significant differences were detected between Pem-Pt 1 B and Pem-Pt in both efficacy and tolerability. These results indicate a potential synergistic effect between taxane and bevacizumab, which has been supported by several preclinical studies. [46] [47] [48] [49] The study by Pasquier et al. 46 suggested that the ability of paclitaxel to inhibit endothelial cell proliferation through G2-M arrest and apoptosis could enhance the effects of bevacizumab through its complementary antitumor activity, as well as, its direct antiangiogenic effects on tumor-associated endothelial cells. In addition, cellular overexpression of Pglycoprotein (P-gp), a member of the ATP-binding cassette transporter-subfamily, was reported as a major mechanism for multidrug resistance (MDR) in tumor cells. 47 Mi et al. 48 discovered that apatinib, a VEGFR TKIs, was able to reverse P-gp mediated MDR by inhibiting its efflux function and subsequently increasing the intracellular accumulation of several P-gp substrate drugs, including paclitaxel, which may also explain the synergistic effect between taxane and bevacizumab. Furthermore, the recent study of Shaked et al. 49 found that microtubule-inhibiting agents like taxane could rapidly induced proangiogenic bone marrow-derived circulating endothelial progenitor (CEP) mobilization and the subsequent tumor homing, which could both be prevented by anti-VEGFR2 blocking antibodies via inhibition of systemic induction of SDF-1a.
With regard to Gem-Pt ) conclude that gemcitabine is inferior to pemetrexed in patients with advanced NS-NSCLC. The ESMO and NCCN guidelines continue to recommend Gem-Pt in the first-line treatment for advanced NS-NSCLC, while the ASCO guidelines elect to exclude Gem-Pt for this population. Results of our study, again in accordance with the ASCO guidelines, showed that GemPt 1 B and Gem-Pt were the least favorable treatments for this population in terms of both efficacy and tolerability (Fig.  4 : the left lower quadrant of the ranking plot). Therefore, in agreement with the preponderance of evidence, our results suggest that Taxane-Pt and Gem-Pt are the most and the least preferable regimen to be used with bevacizumab in the first-line treatment for advanced NS-NSCLC, respectively.
As for the comparison between Pem-Pt 1 B and Pem-Pt, results of the NMA suggested that Pem-Pt 1 B was marginally superior to Pem-Pt in PFS (HR 5 0.58, 95% CI: 0.32-1.0, p 5 0.07) and ORR (OR 5 1.9, 95% CI: 1.0-2.4, p 5 0.05). No significant differences were detected between them for OS and SAE. Moreover, the ranking plot (Fig. 4) indicated that Pem-Pt might be superior to Pem-Pt 1 B in terms of benefit-risk ratio. However, the comparison between these two treatments in the NMA was based on indirect evidence due to the absence of a direct comparison between them. The lack of statistical significance of our results also required extra caution when interpreting these findings. Nevertheless, the highly comparable efficacy and tolerability between Pem-Pt 1 B and Pem-Pt shown in our study underlined the necessity to reconsider the relative benefit and risk of adding bevacizumab to Pem-Pt in the first-line treatment for advanced NS-NSCLC. Future head-to-head trials comparing Pem-Pt 1 B and Pem-Pt are needed to further verify our findings and to justify the use of Pem-Pt 1 B for this population. Until then, adding bevacizumab to Pem-Pt in the firstline setting for advanced NS-NSCLC remains an unanswered question.
Interestingly, our study further found that in terms of the benefit-risk ratio, Pem-Pt appeared to be superior to Taxane-Pt 1 B for untreated advanced NS-NSCLC patients. Two head-to-head trials comparing Taxane-Pt 1 B and Pem-Pt failed to detect significant differences in efficacy and tolerability favoring any of them. 11, 12 Our NMA results indicate that Taxane-Pt 1 B is superior to Pem-Pt in efficacy with modestly enhanced OS (HR 5 0.92, 95% CI: 0.79-1.1, p 5 0.28) and markedly improved PFS (HR 5 0.54, 95% CI: 0.44-0.68, p < 0.001) and ORR (OR 5 2.7, 95% CI: 2.0-3.6, p < 0.001). However, Taxane-Pt 1 B is significantly inferior to Pem-Pt in tolerability (OR 5 7.6, 95% CI: 1.5-43, p 5 0.01). The ranking plot (Fig. 4) , which ranked six treatments based on efficacy and tolerability simultaneously, suggested that Pem-Pt had the best benefit-risk ratio, while Taxane-Pt 1 B showed better efficacy but poorer tolerability. Therefore, in terms of both efficacy and tolerability, Pem-Pt and Taxane-Pt 1 B are the most preferable combinations in the first-line treatment for advanced NS-NSCLC. In comparison to Taxane-Pt 1 B, Pem-Pt seems to have a better benefit-risk ratio. However, whether these differences between them have any clinical significance is a question that can only be answered by future head-to-head trials.
We acknowledge that there are some limitations of our study. First, in common with other meta-analyses, our analysis was limited by its use of summary statistics instead of individual patient data from each trial. Hence, effects of potential prognostic factors on the results could not be assessed and adjusted for. We also did not evaluate specific adverse events separately for the same reason. Second, some included trials involved a small proportion of squamous histology, which might confound our results. One included trial (Boutsikou et al. 33 ) was a single-centered small-scale RCT with a high overall risk of bias. However, we justified the inclusion of the above trials by sensitivity analyses and they were eventually included for the robustness of final results. Third, RCTs included in our study used different versions of toxicity criteria to evaluate SAE, which might lead to potential heterogeneity and inconsistency. Although no significant heterogeneity and inconsistency were detected in our study, extra caution should still be taken while interpreting our findings.
Despite the above limitations, our study confirms that the efficacy of bevacizumab plus platinum-based doublets depends on the chemotherapy regimen itself. In the first-line treatment for advanced NS-NSCLC, Taxane-Pt and Gem-Pt are the most and the least preferable regimens to be used with bevacizumab, respectively. The highly comparable efficacy and tolerability between Pem-Pt 1 B and Pem-Pt shown in our study underlines the need for future head-tohead trials between them to justify the addition of bevacizumab to Pem-Pt for this population. In terms of both efficacy and tolerability, Pem-Pt and Taxane-Pt 1 B are the most preferable combinations in the first-line setting for advanced NS-NSCLC. Pem-Pt seems to have better benefit-risk ratio in comparison to Taxane-Pt 1 B. Nonetheless, the selection between the two treatments in the clinical setting needs to be further informed by randomized controlled trials.
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